Informed Prostate Cancer Patient Support

Oncology grief is the price of caring deeply for patients IPCSG Newsletter | Patient & Caregiver Education Series BLUF (Bottom Line Up Front):   The doctors, nurses, and staff who care for you through prostate cancer are not detached technicians — research confirms they absorb real, lasting grief from patient suffering and loss, and a majority report symptoms of burnout, with hematology/oncology consistently ranked among the most affected specialties in national surveys. This grief is not a flaw in your care team; multiple studies now show it is the by-product of the same empathy that makes them effective clinicians. Understanding this can deepen the trust between patients and the people caring for them, and points toward concrete steps — for clinicians, institutions, and patients alike — that support a sustainable, compassionate oncology workforce. Most of us, as patients living with advanced prostate cancer, focus naturally on our own fear, our own scans, o...

Promising Treatments for Refractory and Resistant Prostate Cancer - Ramesh Narayanan, PhD, MBA - YouTube A Closer Look at the Next Generation of Androgen-Receptor Drugs IPCSG Newsletter | Patient Education & Advocacy | Prepared for the Informed Prostate Cancer Support Group BLUF (Bottom Line Up Front):   A recent "Cancer Patient Lab" webinar featuring Dr. Ramesh Narayanan of the University of Tennessee Health Science Center (UTHSC) offered a clear, patient-level tour of why androgen-receptor (AR) drugs eventually stop working — and what researchers are trying to do about it. The featured experimental drug, originally called ONCT-534 and developed by Dr. Narayanan and Professor Duane Miller, targets a part of the AR that current drugs don't touch, which in theory should also disable the AR "splice variants" that drive the most aggressive, treatment-resistant disease. The webinar's tone was upbeat about a "phase one" trial — but it...